ProPhase LabsPRPH -5.94% Net Current Asset Value is $-5.93 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 1010100% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
ProPhase Labs's net current asset value per share for the quarter that ended in Dec. 2025 was $-5.93.
The historical rank and industry rank for ProPhase Labs's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of ProPhase Labs was 16.20. The lowest was 0.91. And the median was 3.62.
PRPH's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 3.82 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ProPhase Labs (OTCPK:PRPH) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
ProPhase Labs Net Current Asset Value Related Terms
ProPhase Labs Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, IVRO, FUNI: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $-5.93 mean?
ProPhase Labs (PRPH) has a Net Current Asset Value of $-5.93 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on ProPhase Labs and its competitors. Over the past decade, ProPhase Labs' Net Current Asset Value has ranged from 0.91 to 16.20. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Net Current Asset Value too high?
ProPhase Labs' current Net Current Asset Value is $-5.93. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 16.20. Based on the distribution chart, ProPhase Labs ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Net Current Asset Value compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 99 companies for Net Current Asset Value. This places ProPhase Labs in the lower half of its industry. The industry median Net Current Asset Value is 3.82. Historically, ProPhase Labs' own Net Current Asset Value has ranged from 0.91 to 16.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.82, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Net Current Asset Value is $-5.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 85.5% below its estimated fair value. The current Net Current Asset Value is $-5.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Net Current Asset Value is $-5.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 